Towards preventive medicine. High-throughput methods from molecular biology are about to change daily clinical practice

EMBO Reports

Volumn 9, Issue 11, 2008, Pages 1056-1060

  Bosnjak, Hrvojka ^a   Pavelic, Kresimir ^a   Pavelic, Sandra Kraljevic ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; TRASTUZUMAB;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GENETICS; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; COLON CANCER; COLONOSCOPY; CYTOLOGY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DRUG RESEARCH; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOME ANALYSIS; HEALTH PROGRAM; HEALTH STATUS; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN GENOME PROJECT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; METABOLOMICS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NANOMEDICINE; NONHODGKIN LYMPHOMA; OVARY CANCER; PAPANICOLAOU TEST; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; PUBLIC HEALTH SERVICE; REGENERATIVE MEDICINE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TWO DIMENSIONAL GEL ELECTROPHORESIS; UTERINE CERVIX CANCER; VIRUS MUTATION;

EARLY DETECTION OF CANCER; GENOMICS; HUMAN GENOME PROJECT; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; PREVENTIVE MEDICINE;

EID: 55549109006     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2008.198     Document Type: Article

References (25)

1. Alizadeh aa et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 503-511
2. Billig H et al (2007) Present Status and Future Strategy for Medical Research in Europe. Strasbourg, France: European Science Foundation
3. Carrette O, Demalte I, Scherl a, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez Jc (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of alzheimer's disease. Proteomics 3: 1486-1494
4. Chung cH, Bernard PS, Perou cM (2002) Molecular portraits and the family tree of cancer. Nat Genet 32 (Suppl 2): 533-540
5. Clarke W, Silverman Bc, Zhang Z, Chan DW, Klein AS, Molmenti EP (2003) Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 237: 660-665
6. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman Da (2001) Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82: 40-48
7. Espina V, Dettloff KA, Cowherd S, Petricoin EF 3rd, Liotta La (2004) Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 4: 83-93
8. Hampel H, Goernitz A, Buerger K (2003) Advances in the development of biomarkers for Alzheimer's disease: From cSF total [tau] and a[beta](1-42) proteins to phosphorylated [tau] protein. Brain Res Bull 61: 243-253
9. Kallioniemi O (2004) Medicine: Profile of a tumour. Nature 428 379-382
10. Kling J (2007) Diagnosis or drug? EMBO Rep 8: 903-906
11. Kraljevic S, Pavelic K (2005) Navigare necessere est. EMBO Rep 6: 695-700
12. Kraljevic S, Stambrook PJ, Pavelic K (2004) Accelerating drug discovery. EMBO Rep 5: 837-842
13. Kraljevic S, Sedic M, Scott M, Gehrig P, Schlapbach R, Pavelic K (2006) Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view? Cancer Treat Rev 32: 619-629
14. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Rüther E, Kornhuber J, Wiltfang J (2003) The amyloid-[beta] (A[beta]) peptide pattern in cerebrospinal fluid in alzheimer's disease: evidence of a novel carboxyterminally elongated a[beta] peptide. Rapid Commun Mass Spectrom 17: 1291-1296
15. Liotta LA (2001) Cancer: An attractive force in metastasis. Nature 410: 24-25
16. Liotta LA, Clair T (2000) Cancer: Checkpoint for invasion. Nature 405: 287-288
17. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379
18. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456
19. Petricoin EF et al (2002a) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577
20. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA (2002b) Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 1: 683-695
21. Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7: 737-749
22. Staudt LM (2002) Gene expression profiling of lymphoid malignancies. Annu Rev Med 53: 303-318
23. van de Vijver MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
24. Van't Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452: 564-570
25. Varnum SM, Covington CC, Woodbury RL, Petritis K, Kangas LJ, Abdullah MS, Pounds JG, Smith RD, Zangar RC (2003) Proteomic characterization of nipple aspirate fluid: Identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 80: 87-97